Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials

Publisher: John Wiley & Sons Inc

E-ISSN: 1463-1326|17|6|560-565

ISSN: 1462-8902

Source: DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.6, 2015-06, pp. : 560-565

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content